;PMID: 2321243
;source_file_949.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..231] = [t:43..231]
;2)section:[e:235..256] = [t:235..256]
;3)section:[e:260..356] = [t:260..356]
;4)sentence:[e:360..728] = [t:360..728]
;5)sentence:[e:729..956] = [t:729..956]
;6)sentence:[e:957..1036] = [t:957..1036]
;7)sentence:[e:1037..1129] = [t:1037..1129]
;8)sentence:[e:1130..1233] = [t:1130..1233]
;9)sentence:[e:1234..1336] = [t:1234..1336]
;10)sentence:[e:1337..1512] = [t:1337..1512]
;11)sentence:[e:1513..1642] = [t:1513..1642]
;12)sentence:[e:1643..1710] = [t:1643..1710]
;13)sentence:[e:1711..1828] = [t:1711..1828]
;14)sentence:[e:1829..1942] = [t:1829..1942]
;15)sentence:[e:1943..2043] = [t:1943..2043]
;16)sentence:[e:2044..2207] = [t:2044..2207]
;17)section:[e:2211..2255] = [t:2211..2255]

;section 0 Span:0..37
;Toxicology. 1990 Apr 17;61(2):147-59.
(SEC
  (FRAG (NNP:[0..10] Toxicology) (,:[10..11] .) (CD:[12..16] 1990)
        (NNP:[17..20] Apr) (CC:[21..27] 17;61-LRB-) (CD:[27..28] 2)
        (-RRB-:[28..29] -RRB-) (CD:[29..33] :147) (::[33..34] -)
        (CD:[34..36] 59) (.:[36..37] .)))

;sentence 1 Span:43..231
;Differential effects of 12-O-tetradecanoylphorbol 13-acetate on cytochrome 
;P-450-dependent monooxygenase activities in rat hepatoma cells: induction of 
;P-450I and suppression of P-450II.
;[67..103]:substance:"12-O-tetradecanoylphorbol 13-acetate"
;[107..124]:cyp450:"cytochrome  P-450"
;[135..148]:substance:"monooxygenase"
;[197..203]:cyp450:"P-450I"
;[223..230]:cyp450:"P-450II"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[43..55] Differential) (NNS:[56..63] effects))
      (PP (IN:[64..66] of)
        (NP (NN:[67..92] 12-O-tetradecanoylphorbol) (NN:[93..103] 13-acetate)))
      (PP (IN:[104..106] on)
        (NP
          (NP
            (ADJP
              (NML (NN:[107..117] cytochrome) (NN:[119..124] P-450))
              (HYPH:[124..125] -) (JJ:[125..134] dependent))
            (NN:[135..148] monooxygenase) (NNS:[149..159] activities))
          (PP-LOC (IN:[160..162] in)
            (NP (NN:[163..166] rat) (NN:[167..175] hepatoma)
                (NNS:[176..181] cells))))))
    (::[181..182] :)
    (NP
      (NP
        (NP (NN:[183..192] induction))
        (PP (IN:[193..195] of)
          (NP (NN:[197..203] P-450I))))
      (CC:[204..207] and)
      (NP
        (NP (NN:[208..219] suppression))
        (PP (IN:[220..222] of)
          (NP (NN:[223..230] P-450II)))))
    (.:[230..231] .)))

;section 2 Span:235..256
;Roesch SF, Wiebel FJ.
(SEC
  (FRAG (NNP:[235..241] Roesch) (NNP:[242..244] SF) (,:[244..245] ,)
        (NNP:[246..252] Wiebel) (NNP:[253..256] FJ.)))

;section 3 Span:260..356
;GSF-Institute of Toxicology, Gesellschaft fur Strahlen- und Umweltforschung, 
;Neuherberg, F.R.G.
(SEC
  (FRAG (NNP:[260..263] GSF) (HYPH:[263..264] -) (NNP:[264..273] Institute)
        (IN:[274..276] of) (NNP:[277..287] Toxicology) (,:[287..288] ,)
        (NNP:[289..301] Gesellschaft) (NN:[302..305] fur)
        (NNP:[306..315] Strahlen-) (VBD:[316..319] und)
        (NNP:[320..335] Umweltforschung) (,:[335..336] ,)
        (NNP:[338..348] Neuherberg) (,:[348..349] ,) (NNP:[350..356] F.R.G.)))

;sentence 4 Span:360..728
;We have studied the effects of the tumor promoter 12-O-tetradecanoylphorbol 
;13-acetate (TPA) on cytochrome P-450-dependent monooxygenase activities in 
;several differentiated and dedifferentiated Reuber rat hepatoma cell lines
;using  aryl hydrocarbon (benzo[a]pyrene) hydroxylase (AHH), ethoxyresorufin 
;O-deethylase (EROD), and aldrin epoxidase (AE) as test systems.
;[401..409]:substance:"promoter"
;[410..447]:substance:"12-O-tetradecanoylphorbol  13-acetate"
;[449..452]:substance:"TPA"
;[457..473]:cyp450:"cytochrome P-450"
;[484..497]:substance:"monooxygenase"
;[595..640]:substance:"aryl hydrocarbon (benzo[a]pyrene) hydroxylase"
;[642..645]:substance:"AHH"
;[648..677]:substance:"ethoxyresorufin  O-deethylase"
;[679..683]:substance:"EROD"
;[690..706]:substance:"aldrin epoxidase"
;[708..710]:substance:"AE"
(SENT
  (S
    (NP-SBJ (PRP:[360..362] We))
    (VP (VBP:[363..367] have)
      (VP (VBN:[368..375] studied)
        (NP
          (NP (DT:[376..379] the) (NNS:[380..387] effects))
          (PP (IN:[388..390] of)
            (NP
              (NP (DT:[391..394] the) (NN:[395..400] tumor)
                  (NN:[401..409] promoter))
              (NP
                (NP (NN:[410..435] 12-O-tetradecanoylphorbol)
                    (NN:[437..447] 13-acetate))
                (NP (-LRB-:[448..449] -LRB-) (NN:[449..452] TPA)
                    (-RRB-:[452..453] -RRB-)))))
          (PP (IN:[454..456] on)
            (NP
              (ADJP
                (NML (NN:[457..467] cytochrome) (NN:[468..473] P-450))
                (HYPH:[473..474] -) (JJ:[474..483] dependent))
              (NN:[484..497] monooxygenase) (NNS:[498..508] activities))))
        (PP-LOC (IN:[509..511] in)
          (NP (JJ:[513..520] several)
            (NP
              (NP (VBN:[521..535] differentiated)
                (NML-1 (-NONE-:[535..535] *P*)))
              (CC:[536..539] and)
              (NP (VBN:[540..556] dedifferentiated)
                (NML-1 (NNP:[557..563] Reuber) (NN:[564..567] rat)
                       (NN:[568..576] hepatoma) (NN:[577..581] cell)
                       (NNS:[582..587] lines))))))
        (S-MNR
          (NP-SBJ (-NONE-:[587..587] *))
          (VP (VBG:[588..593] using)
            (NP
              (NP
                (NP
                  (NML
                    (NML (NN:[595..599] aryl) (NN:[600..611] hydrocarbon))
                    (NML (-LRB-:[612..613] -LRB-)
                         (NN:[613..627] benzo-LSB-a-RSB-pyrene))
                    (-RRB-:[627..628] -RRB-))
                  (NN:[629..640] hydroxylase))
                (NP (-LRB-:[641..642] -LRB-) (NN:[642..645] AHH)
                    (-RRB-:[645..646] -RRB-)))
              (,:[646..647] ,)
              (NP
                (NP (NN:[648..663] ethoxyresorufin) (NN:[665..677] O-deethylase))
                (NP (-LRB-:[678..679] -LRB-) (NN:[679..683] EROD)
                    (-RRB-:[683..684] -RRB-)))
              (,:[684..685] ,) (CC:[686..689] and)
              (NP
                (NP (NN:[690..696] aldrin) (NN:[697..706] epoxidase))
                (NP (-LRB-:[707..708] -LRB-) (NN:[708..710] AE)
                    (-RRB-:[710..711] -RRB-))))
            (PP-MNR (IN:[712..714] as)
              (NP (NN:[715..719] test) (NNS:[720..727] systems)))))))
    (.:[727..728] .)))

;sentence 5 Span:729..956
;The following  results were obtained: (1) Exposure of cultures to 400 nM TPA
;for 18-24 h  increased AHH activities in the differentiated lines 2sFou,
;H41IEC3/G- and Fao  as well as in the dedifferentiated line 5L,
;1.5-2.5-fold.
;[795..798]:quantitative-value:"400"
;[799..801]:quantitative-units:"nM"
;[802..805]:substance:"TPA"
;[810..815]:quantitative-value:"18-24"
;[816..817]:quantitative-units:"h"
;[829..832]:substance:"AHH"
;[943..955]:quantitative-value:"1.5-2.5-fold"
(SENT
  (S
    (NP-SBJ-2 (DT:[729..732] The) (VBG:[733..742] following)
              (NNS:[744..751] results))
    (VP (VBD:[752..756] were)
      (VP (VBN:[757..765] obtained)
        (NP-2 (-NONE-:[765..765] *))
        (::[765..766] :)
        (S
          (LST (LS:[767..770] -LRB-1-RRB-))
          (NP-SBJ
            (NP
              (NP (NN:[771..779] Exposure))
              (PP (IN:[780..782] of)
                (NP (NNS:[783..791] cultures))))
            (PP (TO:[792..794] to)
              (NP
                (NML (CD:[795..798] 400) (NN:[799..801] nM))
                (NN:[802..805] TPA)))
            (PP-TMP (IN:[806..809] for)
              (NP
                (QP (CD:[810..812] 18) (HYPH:[812..813] -) (CD:[813..815] 24))
                (NN:[816..817] h))))
          (VP (VBD:[819..828] increased)
            (NP (NN:[829..832] AHH) (NNS:[833..843] activities))
            (PP-LOC
              (PP (IN:[844..846] in)
                (NP
                  (NP (DT:[847..850] the) (VBN:[851..865] differentiated)
                      (NNS:[866..871] lines))
                  (NP
                    (NP (NN:[872..877] 2sFou))
                    (,:[877..878] ,)
                    (NP (NN:[879..888] H41IEC3/G) (SYM:[888..889] -))
                    (CC:[890..893] and)
                    (NP (NN:[894..897] Fao)))))
              (CONJP (RB:[899..901] as) (RB:[902..906] well) (IN:[907..909] as))
              (PP (IN:[910..912] in)
                (NP
                  (NP (DT:[913..916] the) (VBN:[917..933] dedifferentiated)
                      (NN:[934..938] line))
                  (NP (NN:[939..941] 5L)))))
            (,:[941..942] ,)
            (ADVP-EXT
              (QP (CD:[943..946] 1.5) (HYPH:[946..947] -) (CD:[947..950] 2.5))
              (HYPH:[950..951] -) (RB:[951..955] fold))))))
    (.:[955..956] .)))

;sentence 6 Span:957..1036
;The phorbol ester did  not affect AHH activity in the dedifferentiated line
;H5.
;[961..974]:substance:"phorbol ester"
;[991..994]:substance:"AHH"
(SENT
  (S
    (NP-SBJ (DT:[957..960] The)
       (NN:[961..968] phorbol) (NN:[969..974] ester))
    (VP (VBD:[975..978] did) (RB:[980..983] not)
      (VP (VB:[984..990] affect)
        (NP (NN:[991..994] AHH) (NN:[995..1003] activity))
        (PP (IN:[1004..1006] in)
          (NP
            (NP (DT:[1007..1010] the) (VBN:[1011..1027] dedifferentiated)
                (NN:[1028..1032] line))
            (NP (NN:[1033..1035] H5))))))
    (.:[1035..1036] .)))

;sentence 7 Span:1037..1129
;(2) EROD, a marker for  P-450I, was induced by the phorbol ester to a similar
;degree as AHH.
;[1041..1045]:substance:"EROD"
;[1061..1067]:cyp450:"P-450I"
;[1088..1101]:substance:"phorbol ester"
;[1125..1128]:substance:"AHH"
(SENT
  (S
    (LST (LS:[1037..1040] -LRB-2-RRB-))
    (NP-SBJ-1
      (NP (NN:[1041..1045] EROD))
      (,:[1045..1046] ,)
      (NP
        (NP (DT:[1047..1048] a) (NN:[1049..1055] marker))
        (PP (IN:[1056..1059] for)
          (NP (NN:[1061..1067] P-450I)))))
    (,:[1067..1068] ,)
    (VP (VBD:[1069..1072] was)
      (VP (VBN:[1073..1080] induced)
        (NP-1 (-NONE-:[1080..1080] *))
        (PP (IN:[1081..1083] by)
          (NP (DT:[1084..1087] the)
             (NN:[1088..1095] phorbol) (NN:[1096..1101] ester)))
        (PP (TO:[1102..1104] to)
          (NP
            (NP (DT:[1105..1106] a) (JJ:[1107..1114] similar)
                (NN:[1115..1121] degree))
            (PP (IN:[1122..1124] as)
              (NP (NN:[1125..1128] AHH)))))))
    (.:[1128..1129] .)))

;sentence 8 Span:1130..1233
;(3) A  monoclonal antibody directed against P-450I strongly inhibited the AHH
;activity  induced by TPA.
;[1137..1156]:substance:"monoclonal antibody"
;[1174..1180]:cyp450:"P-450I"
;[1204..1207]:substance:"AHH"
;[1229..1232]:substance:"TPA"
(SENT
  (S
    (LST (LS:[1130..1133] -LRB-3-RRB-))
    (NP-SBJ
      (NP (DT:[1134..1135] A)
         (JJ:[1137..1147] monoclonal) (NN:[1148..1156] antibody))
      (VP (VBN:[1157..1165] directed)
        (NP (-NONE-:[1165..1165] *))
        (PP (IN:[1166..1173] against)
          (NP (NN:[1174..1180] P-450I)))))
    (ADVP (RB:[1181..1189] strongly))
    (VP (VBD:[1190..1199] inhibited)
      (NP
        (NP (DT:[1200..1203] the) (NN:[1204..1207] AHH)
            (NN:[1208..1216] activity))
        (VP (VBN:[1218..1225] induced)
          (NP (-NONE-:[1225..1225] *))
          (PP (IN:[1226..1228] by)
            (NP (NN:[1229..1232] TPA))))))
    (.:[1232..1233] .)))

;sentence 9 Span:1234..1336
;(4) The onset of AHH or EROD induction by TPA was much later  than that
;elicited by benz[a]anthracene.
;[1251..1254]:substance:"AHH"
;[1258..1262]:substance:"EROD"
;[1276..1279]:substance:"TPA"
;[1318..1335]:substance:"benz[a]anthracene"
(SENT
  (S
    (LST (LS:[1234..1237] -LRB-4-RRB-))
    (NP-SBJ
      (NP
        (NP (DT:[1238..1241] The) (NN:[1242..1247] onset))
        (PP (IN:[1248..1250] of)
          (NP (NN:[1251..1254] AHH))))
      (CC:[1255..1257] or)
      (NP
        (NP (NN:[1258..1262] EROD) (NN:[1263..1272] induction))
        (PP (IN:[1273..1275] by)
          (NP (NN:[1276..1279] TPA)))))
    (VP (VBD:[1280..1283] was)
      (ADJP-PRD
        (ADJP (RB:[1284..1288] much) (RBR:[1289..1294] later))
        (PP (IN:[1296..1300] than)
          (NP
            (NP (DT:[1301..1305] that))
            (VP (VBN:[1306..1314] elicited)
              (NP (-NONE-:[1314..1314] *))
              (PP (IN:[1315..1317] by)
                (NP (NN:[1318..1335] benz-LSB-a-RSB-anthracene))))))))
    (.:[1335..1336] .)))

;sentence 10 Span:1337..1512
;(6) In contrast to the induction of AHH  and EROD, TPA decreased AE activity,
;a marker for P-450II, by about 50% in all  the cell lines containing this
;monooxygenase activity.
;[1373..1376]:substance:"AHH"
;[1382..1386]:substance:"EROD"
;[1388..1391]:substance:"TPA"
;[1402..1404]:substance:"AE"
;[1428..1435]:cyp450:"P-450II"
;[1446..1449]:quantitative-value:"50%"
;[1489..1502]:substance:"monooxygenase"
(SENT
  (S
    (LST (LS:[1337..1340] -LRB-6-RRB-))
    (PP (IN:[1341..1343] In)
      (NP
        (NP (NN:[1344..1352] contrast))
        (PP (TO:[1353..1355] to)
          (NP
            (NP (DT:[1356..1359] the) (NN:[1360..1369] induction))
            (PP (IN:[1370..1372] of)
              (NP (NN:[1373..1376] AHH) (CC:[1378..1381] and)
                  (NN:[1382..1386] EROD)))))))
    (,:[1386..1387] ,)
    (NP-SBJ (NN:[1388..1391] TPA))
    (VP (VBD:[1392..1401] decreased)
      (NP
        (NP (NN:[1402..1404] AE) (NN:[1405..1413] activity))
        (,:[1413..1414] ,)
        (NP
          (NP (DT:[1415..1416] a) (NN:[1417..1423] marker))
          (PP (IN:[1424..1427] for)
            (NP (NN:[1428..1435] P-450II)))))
      (,:[1435..1436] ,)
      (PP-EXT (IN:[1437..1439] by)
        (NP
          (QP (RB:[1440..1445] about) (CD:[1446..1448] 50))
          (NN:[1448..1449] %)))
      (PP-LOC (IN:[1450..1452] in)
        (NP
          (NP (PDT:[1453..1456] all) (DT:[1458..1461] the)
              (NN:[1462..1466] cell) (NNS:[1467..1472] lines))
          (VP (VBG:[1473..1483] containing)
            (NP (DT:[1484..1488] this) (NN:[1489..1502] monooxygenase)
                (NN:[1503..1511] activity))))))
    (.:[1511..1512] .)))

;sentence 11 Span:1513..1642
;(7) The  half-maximum-effect concentration of TPA for inducing or suppressing
;AHH and AE,  respectively, was approximately 20 nM.
;[1559..1562]:substance:"TPA"
;[1591..1594]:substance:"AHH"
;[1599..1601]:substance:"AE"
;[1636..1638]:quantitative-value:"20"
;[1639..1641]:quantitative-units:"nM"
(SENT
  (S
    (LST (LS:[1513..1516] -LRB-7-RRB-))
    (NP-SBJ
      (NP (DT:[1517..1520] The)
        (NML (RB:[1522..1526] half) (HYPH:[1526..1527] -)
             (JJ:[1527..1534] maximum) (HYPH:[1534..1535] -)
             (NN:[1535..1541] effect))
        (NN:[1542..1555] concentration))
      (PP (IN:[1556..1558] of)
        (NP (NN:[1559..1562] TPA)))
      (PP (IN:[1563..1566] for)
        (S-NOM
          (NP-SBJ (-NONE-:[1566..1566] *))
          (VP (VBG:[1567..1575] inducing) (CC:[1576..1578] or)
              (VBG:[1579..1590] suppressing)
            (NP
              (NP (NN:[1591..1594] AHH) (CC:[1595..1598] and)
                  (NN:[1599..1601] AE))
              (,:[1601..1602] ,))
            (ADVP (RB:[1604..1616] respectively))))))
    (,:[1616..1617] ,)
    (VP (VBD:[1618..1621] was)
      (NP-PRD
        (QP (RB:[1622..1635] approximately) (CD:[1636..1638] 20))
        (NN:[1639..1641] nM)))
    (.:[1641..1642] .)))

;sentence 12 Span:1643..1710
;(8) TPA did not interfere with AHH  induction by benz[a]anthracene.
;[1647..1650]:substance:"TPA"
;[1674..1677]:substance:"AHH"
;[1692..1709]:substance:"benz[a]anthracene"
(SENT
  (S
    (LST (LS:[1643..1646] -LRB-8-RRB-))
    (NP-SBJ (NN:[1647..1650] TPA))
    (VP (VBD:[1651..1654] did) (RB:[1655..1658] not)
      (VP (VB:[1659..1668] interfere)
        (PP-CLR (IN:[1669..1673] with)
          (NP
            (NP (NN:[1674..1677] AHH) (NN:[1679..1688] induction))
            (PP (IN:[1689..1691] by)
              (NP (NN:[1692..1709] benz-LSB-a-RSB-anthracene)))))))
    (.:[1709..1710] .)))

;sentence 13 Span:1711..1828
;However, the phorbol ester moderately decreased  AHH induction and markedly
;suppressed AE induction by dexamethasone.
;[1724..1737]:substance:"phorbol ester"
;[1760..1763]:substance:"AHH"
;[1798..1800]:substance:"AE"
;[1814..1827]:substance:"dexamethasone"
(SENT
  (S
    (ADVP (RB:[1711..1718] However))
    (,:[1718..1719] ,)
    (NP-SBJ (DT:[1720..1723] the)
       (NN:[1724..1731] phorbol) (NN:[1732..1737] ester))
    (VP
      (VP
        (ADVP (RB:[1738..1748] moderately))
        (VBD:[1749..1758] decreased)
        (NP (NN:[1760..1763] AHH) (NN:[1764..1773] induction)))
      (CC:[1774..1777] and)
      (VP
        (ADVP (RB:[1778..1786] markedly))
        (VBD:[1787..1797] suppressed)
        (NP
          (NP (NN:[1798..1800] AE) (NN:[1801..1810] induction))
          (PP (IN:[1811..1813] by)
            (NP (NN:[1814..1827] dexamethasone))))))
    (.:[1827..1828] .)))

;sentence 14 Span:1829..1942
;The results  indicate that TPA simultaneously induces P-450I and suppresses
;P-450II forms in  rat hepatoma cells.
;[1856..1859]:substance:"TPA"
;[1883..1889]...[1913..1918]:cyp450:"P-450I"..."forms"
;[1905..1918]:cyp450:"P-450II forms"
(SENT
  (S
    (NP-SBJ (DT:[1829..1832] The) (NNS:[1833..1840] results))
    (VP (VBP:[1842..1850] indicate)
      (SBAR (IN:[1851..1855] that)
        (S
          (NP-SBJ (NN:[1856..1859] TPA))
          (ADVP (RB:[1860..1874] simultaneously))
          (VP
            (VP (VBZ:[1875..1882] induces)
              (NP (NN:[1883..1889] P-450I)
                (NML-2 (-NONE-:[1889..1889] *P*)))
              (PP-1 (-NONE-:[1889..1889] *RNR*)))
            (CC:[1890..1893] and)
            (VP (VBZ:[1894..1904] suppresses)
              (NP (NN:[1905..1912] P-450II)
                (NML-2 (NNS:[1913..1918] forms)))
              (PP-1 (-NONE-:[1918..1918] *RNR*)))
            (PP-1 (IN:[1919..1921] in)
              (NP (NN:[1923..1926] rat) (NN:[1927..1935] hepatoma)
                  (NNS:[1936..1941] cells)))))))
    (.:[1941..1942] .)))

;sentence 15 Span:1943..2043
;P-450I induction by TPA in these cells did not appear to  depend on their
;status of differentiation.
;[1943..1949]:cyp450:"P-450I"
;[1963..1966]:substance:"TPA"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1943..1949] P-450I) (NN:[1950..1959] induction))
      (PP (IN:[1960..1962] by)
        (NP (NN:[1963..1966] TPA)))
      (PP-LOC (IN:[1967..1969] in)
        (NP (DT:[1970..1975] these) (NNS:[1976..1981] cells))))
    (VP (VBD:[1982..1985] did) (RB:[1986..1989] not)
      (VP (VB:[1990..1996] appear)
        (S
          (NP-SBJ-1 (-NONE-:[1996..1996] *))
          (VP (TO:[1997..1999] to)
            (VP (VB:[2001..2007] depend)
              (PP-CLR (IN:[2008..2010] on)
                (NP
                  (NP (PRP$:[2011..2016] their) (NN:[2017..2023] status))
                  (PP (IN:[2024..2026] of)
                    (NP (NN:[2027..2042] differentiation))))))))))
    (.:[2042..2043] .)))

;sentence 16 Span:2044..2207
;Furthermore, the results suggest that  the mechanism of P-450I induction by
;TPA differs from that elicited by  polycyclic aromatic hydrocarbons or
;glucocorticoids.
;[2100..2106]:cyp450:"P-450I"
;[2120..2123]:substance:"TPA"
;[2155..2187]:substance:"polycyclic aromatic hydrocarbons"
;[2191..2206]:substance:"glucocorticoids"
(SENT
  (S
    (ADVP (RB:[2044..2055] Furthermore))
    (,:[2055..2056] ,)
    (NP-SBJ (DT:[2057..2060] the) (NNS:[2061..2068] results))
    (VP (VBP:[2069..2076] suggest)
      (SBAR (IN:[2077..2081] that)
        (S
          (NP-SBJ
            (NP (DT:[2083..2086] the) (NN:[2087..2096] mechanism))
            (PP (IN:[2097..2099] of)
              (NP
                (NP (NN:[2100..2106] P-450I) (NN:[2107..2116] induction))
                (PP (IN:[2117..2119] by)
                  (NP (NN:[2120..2123] TPA))))))
          (VP (VBZ:[2124..2131] differs)
            (PP-CLR (IN:[2132..2136] from)
              (NP
                (NP (DT:[2137..2141] that))
                (VP (VBN:[2142..2150] elicited)
                  (NP (-NONE-:[2150..2150] *))
                  (PP (IN:[2151..2153] by)
                    (NP-LGS
                      (NP (JJ:[2155..2165] polycyclic)
                          (JJ:[2166..2174] aromatic)
                          (NNS:[2175..2187] hydrocarbons))
                      (CC:[2188..2190] or)
                      (NP (NNS:[2191..2206] glucocorticoids)))))))))))
    (.:[2206..2207] .)))

;section 17 Span:2211..2255
;PMID: 2321243 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2211..2215] PMID) (::[2215..2216] :) (CD:[2217..2224] 2321243)
        (NN:[2225..2226] -LSB-) (NNP:[2226..2232] PubMed) (::[2233..2234] -)
        (NN:[2235..2242] indexed) (IN:[2243..2246] for)
        (NNP:[2247..2255] MEDLINE-RSB-)))
